skip to main content

Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study.(Research article)(Report)

Newton, Melissa J. ; Hayes, Sandi C. ; Janda, Monika ; Webb, Penelope M. ; Obermair, Andreas ; Eakin, Elizabeth G. ; Wyld, David ; Gordon, Louisa G. ; Beesley, Vanessa L.

BMC Cancer, Sept 8, 2011, Vol.11, p.389 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
  • Título:
    Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study.(Research article)(Report)
  • Autor: Newton, Melissa J. ; Hayes, Sandi C. ; Janda, Monika ; Webb, Penelope M. ; Obermair, Andreas ; Eakin, Elizabeth G. ; Wyld, David ; Gordon, Louisa G. ; Beesley, Vanessa L.
  • Assuntos: Walking -- Health Aspects ; Adjuvant Chemotherapy -- Health Aspects ; Ovarian Cancer -- Drug Therapy ; Ovarian Cancer -- Research
  • É parte de: BMC Cancer, Sept 8, 2011, Vol.11, p.389
  • Descrição: Background Exercise interventions during adjuvant cancer therapy have been shown to increase functional capacity, relieve fatigue and distress and may assist rates of chemotherapy completion. These studies have been limited to breast, gastric and mixed cancer groups and it is not yet known if a similar intervention is even feasible among women with ovarian cancer. We aimed to assess safety, feasibility and potential effect of a walking intervention in women undergoing chemotherapy for ovarian cancer. Methods Women newly diagnosed with ovarian cancer were recruited to participate in an individualised walking intervention throughout chemotherapy and were assessed pre- and post-intervention. Feasibility measures included session adherence, compliance with exercise physiologist prescribed walking targets and self-reported program acceptability. Changes in objective physical functioning (6-minute walk test), self-reported distress (Hospital Anxiety and Depression Scale), symptoms (Memorial Symptom Assessment Scale - Physical) and quality of life (Functional Assessment of Cancer Therapy - Ovarian) were calculated, and chemotherapy completion and adverse intervention effects recorded. Results Seventeen women were enrolled (63% recruitment rate). Mean age was 60 years (SD = 8 years), 88% were diagnosed with FIGO stage III or IV disease, 14 women underwent adjuvant and three neo-adjuvant chemotherapy. On average, women adhered to > 80% of their intervention sessions and complied with 76% of their walking targets, with the majority walking four days a week at moderate intensity for 30 minutes per session. Meaningful improvements were found in physical functioning, physical symptoms, physical well-being and ovarian cancer-specific quality of life. Most women (76%) completed [greater than or equal to]85% of their planned chemotherapy dose. There were no withdrawals or serious adverse events and all women reported the program as being helpful. Conclusions These positive preliminary results suggest that this walking intervention for women receiving chemotherapy for ovarian cancer is safe, feasible and acceptable and could be used in development of future work. Trial registration ACTRN12609000252213
  • Idioma: English

Buscando em bases de dados remotas. Favor aguardar.